Norvège - norvégien - Statens legemiddelverk

alk-abelló as - histamindihydroklorid - oppløsning til prikktest

Norvège - norvégien - Statens legemiddelverk

alk-abelló as - histamindihydroklorid - oppløsning til prikktest - 10 mg/ ml

Norvège - norvégien - Statens legemiddelverk

alk-abelló as - allergen av hengebjørk - oppløsning til prikktest - 10 hep

Norvège - norvégien - Statens legemiddelverk

alk-abelló as - allergen av husstøvmidd, dermatophagoides pteronyssinus - oppløsning til prikktest - 10 hep

Norvège - norvégien - Statens legemiddelverk

alk-abelló as - allergen av phleum pratense - oppløsning til prikktest - 10 hep

Norvège - norvégien - Statens legemiddelverk

accord healthcare b.v. - cytarabin - injeksjons-/infusjonsvæske, oppløsning - 20 mg/ ml

Union européenne - norvégien - EMA (European Medicines Agency)

janssen-cilag international n.v. - daratumumab - multippelt myelom - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. i kombinasjon med bortezomib, thalidomid og dexamethasone for behandling av voksne pasienter med nydiagnostisert myelomatose som er kvalifisert for autologous stamcelletransplantasjon. i kombinasjon med lenalidomide og dexamethasone, eller bortezomib og dexamethasone, for behandling av voksne pasienter med myelomatose som har mottatt minst ett før behandling. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. som monoterapi for behandling av voksne pasienter med tilbakefall og ildfaste myelomatose, som før terapi inkludert en proteasome hemmer og en immunmodulerende agent og som har vist progresjon av sykdommen på den siste terapi. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

Union européenne - norvégien - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamide - prostata neoplasmer - endokrin terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Norvège - norvégien - Statens legemiddelverk

teva sweden ab - takrolimus - kapsel, hard - 5 mg

Union européenne - norvégien - EMA (European Medicines Agency)

teva b.v. - zoledronsyre - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - legemidler til behandling av bein sykdommer - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. behandling av pagets sykdom i beinet i voksne.